hla 分型技术
DESCRIPTION
HLA 分型技术. 上海交通大学医学院 彭奕冰 主任技师. Major Histocompatibility Complex (MHC). What is MHC? HLA H-2 Minor histocompatibility antigens. Significance of the MHC. role in immune response role in organ transplantation role in predisposition to disease. Genetic barriers to transplantation. - PowerPoint PPT PresentationTRANSCRIPT
1
HLA分型技术
上海交通大学医学院彭奕冰 主任技师
2
Major Histocompatibility Complex(MHC)
Major Histocompatibility Complex(MHC)
What is MHC?– HLA– H-2– Minor histocompatibility antigens
What is MHC?– HLA– H-2– Minor histocompatibility antigens
3
Significance of the MHCSignificance of the MHCSignificance of the MHCSignificance of the MHC
role in immune responserole in immune response role in organ transplantationrole in organ transplantation role in predisposition to diseaserole in predisposition to disease
role in immune responserole in immune response role in organ transplantationrole in organ transplantation role in predisposition to diseaserole in predisposition to disease
5
Genetic barriers to transplantationGenetic barriers to transplantationGenetic barriers to transplantationGenetic barriers to transplantation
• autologous: in the same individual (autograft)
• isologous: between genetically Identical individuals (isograft), i.e., identical twins (inbred animals)
• homologous: between individuals of the same species (allograft)
• heterologous: between individuals different species (xenograft)
• autologous: in the same individual (autograft)
• isologous: between genetically Identical individuals (isograft), i.e., identical twins (inbred animals)
• homologous: between individuals of the same species (allograft)
• heterologous: between individuals different species (xenograft)
6
Principles of transplantationPrinciples of transplantationPrinciples of transplantationPrinciples of transplantation
7
Minor histocompatibility antigensMinor histocompatibility antigensand graft survivaland graft survival
Minor histocompatibility antigensMinor histocompatibility antigensand graft survivaland graft survival
minor histocompatibility antigens also cause rejection
The rejection time is variable but longer than that for major histocompatibility antigen
They have additive effects
minor histocompatibility antigens also cause rejection
The rejection time is variable but longer than that for major histocompatibility antigen
They have additive effects
8
Graft versus host (GVH) Graft versus host (GVH) diseasedisease
Graft versus host (GVH) Graft versus host (GVH) diseasedisease
9
GVH disease in humansGVH disease in humansGVH disease in humansGVH disease in humans
10
The human MHC genesThe human MHC genesThe human MHC genesThe human MHC genes
class II c lass ID P D Q D R B C A
B C A
D P D Q D R
1 2 2 2 1 1 9 3 1 2 2 1 3
11
The mouse MHC genesThe mouse MHC genesThe mouse MHC genesThe mouse MHC genes
I
DK
A E
class II c lass Iclass I class III(C4, factor-B ,TNF, etc.)
12
Polymorphism of MHC antigens Polymorphism of MHC antigens (based on phenotype)(based on phenotype)
Polymorphism of MHC antigens Polymorphism of MHC antigens (based on phenotype)(based on phenotype)
HLA基因系统的多态性及一些主要基因座位的等位基因数正式命名显示多态性的 HLA基因座位有 31个,共 2 320个等位基因。 图中所示为常见基因座位的等位基因数。
13
The inheritance of MHC genesThe inheritance of MHC genesThe inheritance of MHC genesThe inheritance of MHC genes
Jack Jill
D P
D Q
D R
B
C
A
1 2 3 4
Bo Kim M o Lee
1 3 41 2 3 42
14
Crossing overCrossing overresults in new haplotypesresults in new haplotypes
15
MHC products expressed on cellsMHC products expressed on cellsMHC products expressed on cellsMHC products expressed on cells
If Jack and Jill have four children; Bo, Kim, Mo and Lee
They’ll all inherit antigens of the parental MHC
Oft their haplotypes will be of the father or mother
Unless during meiosis, a crossover should occur
16
Class-I expressed on all nucleated cells in man, and also on erythrocytes in mice.
Class-II expressed primarily on antigen presenting cells (dendritic cells, macrophages and B cells, etc.)
Differential expression Differential expression of MHC antigensof MHC antigens
17
Alloreactivity of T cells:MLR and CTL generationAlloreactivity of T cells:
MLR and CTL generation
CD4+TH1
CD8+CTL
CD8+preCTL
18
Alloreactivity of T cellsAlloreactivity of T cells
T CELLT CELL
DRW 11DRW 17
PositiveSelection
ThymusAlloreaction
(MLR)
Proliferation and
Differentiation
19
Inflammation
lysis
ADCC
lysis
IL2, IFN
TNF, NO2
IL2, IL4, IL5
IL2, TNF, IFN
rejection
Mechanisms of graft rejectionMechanisms of graft rejectionMechanisms of graft rejectionMechanisms of graft rejection
20
Tempo of rejection reactionTempo of rejection reactionTempo of rejection reactionTempo of rejection reaction
type of rejection
time takentime taken causecause
chronicchronic months-yearsmonths-years unclear causes: cross reactive unclear causes: cross reactive Ab, immune complexes, slow Ab, immune complexes, slow cellular reaction, tolerance cellular reaction, tolerance breakdown, disease recurrencebreakdown, disease recurrence
accelerated days reactivation of sensitized T cells (secondary response)
acute days-weeks
primary activation of T cells
hyperacute minutes- hours preformed anti-donor antibodies and complement
21
A, B & DR matching and graft A, B & DR matching and graft survivalsurvival
A, B & DR matching and graft A, B & DR matching and graft survivalsurvival
22
Removal of T cells from marrow graftRemoval of T cells from marrow graft
Magnet
Magnetic antibodies
23
HLA and disease associationHLA and disease associationHLA and disease associationHLA and disease association
DiseaseDisease Associated Associated allelesalleles Frequency inFrequency in
Relative Relative riskriskpatientspatients controlcontrol
Ankylsoing spondylitisAnkylsoing spondylitis
Reiter’s diseaseReiter’s disease
Acute anterior uveitisAcute anterior uveitis
Psoriasis vulgarisPsoriasis vulgaris
Dermatitis herpetiformisDermatitis herpetiformis
B27B27
B27B27
B27B27
CW6CW6
DR3DR3
99
7979
5252
8787
8585
99
99
99
3333
2626
87.487.4
37.037.0
10.410.4
13.313.3
15.415.4
24
HLA抗原检测法
25
微量细胞毒试验
原理 当特异性抗体与淋巴细胞表面 HLA分子结合,激活补体,使细胞溶解。在显微镜下可见细胞被活性染料着色。 T淋巴细胞只表达 HLA I分子,如欲测
定 HLA II类分子,需用B细胞。
26
微量细胞毒试验 HLA I类分型法
方法1. 加板: Terasaki板中加入特异性抗 HLA I类分子抗体。
2. 分离 PBMC。制成浓度为 1106/ml的细胞悬液。3. 每孔内加入 1l细胞悬液。4. 室温培育 30min 。5. 1 l兔补体。室温培育 60min 。6. 每孔内加入 5l 5%伊红水溶液。室温 5min 。7. 每孔内加 37%甲醛固定。8. 倒置相差显微镜下观察结果。
27
微量细胞毒试验 HLA II类分型法
与 HLAI类分型法区别1.须用富含B细胞的淋巴细胞悬液。2.抗体与细胞培育时间为 1h 。
3.加补体后培育时间为 2h 。
28
微量细胞毒试验
应用实践 个体 HLA分型可用于移植前供者和受者配型,亲子鉴定,法医鉴定等。
29
交叉配型
用于测定受者血清中受含有抗供者 HLA
的抗体。如受者血清中具有抗供者红细胞血型抗原抗体和 /或抗白细胞抗原抗体,会引起超急排异反应。所以移植前应作红细胞血型测定,以及测定患者血清中是否具有抗供者 HLA抗体。
30
交叉配型方法
1. 分离供体 PBMC 。
2. 分离受者血清,作 1: 2, 1: 4和 1: 8稀释。加入 Terasaki板,每孔 1l 。
其余步骤同微量细胞毒试验。
如结果为阳性,表明受者血清中具有抗供者 HLA
抗体。
31
细胞学分型法
细胞学分型法已被血清学和分子生物学方法代替。单相混合淋巴细胞培养实验还在使用。
32
分子生物学技术为基础的 HLA分型法
原理
HLA的多态性是由基因中核苷酸序列突变引起的。同一基因的不同等位基因之间核苷酸序列大多是相同的,变异集中在几个 DNA片段中。在这些片断中,不同的等位基因具有特定的序列。测定这些片段的 DNA序列就可以确定等位基因。
33
变异片段 变异片段 变异片段
34
a b c dac Aac ATCGGTCGGTCAAGGTCAAGGCCTATCCCTATCGATTGCGTAGGCGATTGCGTAGGC
bd ATCGGTbd ATCGGTCAAGCAAGGCCTATCGGCCTATCGATTGATTGCGTAGGCCGTAGGC
ac Aac ATCGGTCGGTCAAGGTCAAGGCCTATCCCTATCGATTGCGTAGGCGATTGCGTAGGC
ad Aad ATCGGTCGGTCAAGGCCTATCGTCAAGGCCTATCGATTGATTGCGTAGGCCGTAGGC
bc bc ATCGGTATCGGTCAAGCAAGGGCCTATCCCTATCGATTGCGTAGGCGATTGCGTAGGC
35
根据片段组合指定等位基因
acac
acac
bcbc
ad ad
bdbd
acacefef
ghgh
efef
mlml
jkjk
oxox
rtrt
wqwq
svsv
zpzp